Cargando…
Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study
Melanoma of unknown primary (MUP) may have a different biology to melanoma of known primary, but clinical trials of novel therapies (e.g., immune checkpoint or BRAF/MEK inhibitors) have not reported the outcomes in this population. We therefore evaluated the overall survival (OS) among patients with...
Autores principales: | Verver, D, van der Veldt, AAM, van Akkooi, ACJ, Verhoef, C, Grünhagen, DJ, Louwman, WJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900034/ https://www.ncbi.nlm.nih.gov/pubmed/30801710 http://dx.doi.org/10.1002/ijc.32229 |
Ejemplares similares
-
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
por: Verver, Danielle, et al.
Publicado: (2021) -
Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study
por: Zhou, Catherine, et al.
Publicado: (2021) -
Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma
por: Mulder, E.E.A.P., et al.
Publicado: (2020) -
Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: A multicentre study
por: Clayton, Bethan, et al.
Publicado: (2022) -
Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation
por: Mulder, E.E.A.P., et al.
Publicado: (2021)